Pathogenesis of malformations in a rodent model for Smith-Lemli-Opitz syndrome

Am J Med Genet. 1997 Jan 31;68(3):328-37. doi: 10.1002/(sici)1096-8628(19970131)68:3<328::aid-ajmg15>;2-v.


The fact that Smith-Lemli-Opitz syndrome (SLOS), a syndrome comprising major malformations involving a number of organ systems, results from an abnormality in cholesterol biosynthesis, was discovered only recently. Utilizing a drug (BM 15.766) to inhibit the same step in cholesterol biosynthesis as is abnormal in those affected with SLOS, we have developed a rat model that presents with abnormalities observed as early as gestational day 12 that appear to be consistent with some of those subsequent malformations that comprise the human syndrome. Abnormalities of the brain and face include deficiency in the midline region of the upper face, narrowing of the forebrain hemispheres and of the cerebral aqueduct, and deficiency in the developing lower jaw. Associated pathogenesis, as observed on gestational day 11 in histological sections and with scanning electron microscopy, involves abnormal cell populations at the rim of the developing forebrain and in the alar plate of the lower midbrain and hind-brain. The affected cells appear abnormally rounded up, having apparently lost their normal cell contacts. The potential basis for the selective vulnerability of this cell population and the impact of its vulnerability relative to subsequent dysmorphogenesis is discussed.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cholesterol / blood
  • Disease Models, Animal
  • Embryo, Mammalian / ultrastructure
  • Female
  • Piperazines / toxicity*
  • Pregnancy
  • Rats
  • Rats, Wistar
  • Smith-Lemli-Opitz Syndrome / chemically induced
  • Smith-Lemli-Opitz Syndrome / pathology*
  • Teratogens / toxicity*


  • Piperazines
  • Teratogens
  • BM 15766
  • Cholesterol